Expert Discusses the Presidential Administration’s Narrowing of COVID-19 Vaccines

For pharmacists standing on the front lines of public health, the ground beneath the COVID-19 vaccine landscape is shifting. Once characterized by universal and routine recommendations, the current administration—led by HHS Secretary Robert F. Kennedy Jr.—is orchestrating a fundamental reframing of how these immunizations exist within the American health care system.

“Pharmacists understand there's an important distinction between a formal market removal and practical access,” Jeff Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, told Drug Topics. “The more realistic concern is probably not the sudden market withdrawal but a progressive narrowing of indications, recommendations, or payer coverage, which really can effectively reduce access and uptake, even without an official removal of the vaccine.”

The past year has seen a series of high-stakes regulatory pivots. Most notably, federal funding has been pulled from mRNA research and pandemic preparedness. Simultaneously, the FDA has pivoted away from universal guidance toward a risk-focused model that prioritizes seniors aged 65+ and those with high-risk comorbidities.

In part 1 of our interview with Goad, he provided much-needed insights into the ongoing narratives circulating about the COVID-19 vaccine and other sentiments coming from the federal government. Listen to a national leader in the vaccine space and just how he and his pharmacy peers are addressing this ever-evolving landscape.

“Even when a product remains FDA approved, changes in recommendations, coverage, policy, procurement, and even public messaging can significantly limit real-world availability in the near term,” concluded Goad.

READ MORE: COVID-19 Resource Center

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.